The Morning: An underused Covid treatment

Paxlovid could save lives, but most people still don't get it.

View in browser|nytimes.com Continue reading the main story January 31, 2023 By German Lopez Good morning. Doctors are now a major barrier to Paxlovid. Paxlovid being manufactured in Italy in 2021.Pfizer, via Reuters Unnecessary deaths Covid is still linked to hundreds of deaths a day in the U.S. We have a treatment that could bring down those deaths: a prescribed pill called Paxlovid, which reduces the severity of a Covid infection, particularly among older and more vulnerable Americans. Yet that treatment remains underused. Doctors prescribed it in about 45 percent of recorded Covid cases nationwide during the first two weeks of January, according to White House data. In some states, Paxlovid is given in less than 25 or even 20 percent of recorded cases. (Those are likely overestimates because cases are underreported.) Why is Paxlovid still relatively untapped? Part of the answer lies in a lack of public awareness. Some Covid patients also may decide that they don't need Paxlovid because they are already vaccinated, have had Covid before or are younger. (My colleagues explained why even mild cases often still warrant a dose of Paxlovid.) The political polarization of the virus plays a role, too: People in blue states are more likely to use Paxlovid than in red states. Experts have increasingly pointed to another explanation for Paxlovid's underuse: Doctors still resist prescribing it. Today's newsletter will focus on that cause. Physician resistance Some doctors have concerns that are rooted in real issues with Paxlovid and inform their reluctance to prescribe it. But experts are unconvinced that those fears are enough to avoid prescribing Paxlovid altogether, especially to older and higher-risk patients. "What I'm doing for a living is weighing the benefits and the risks for everything," said Dr. Robert Wachter, the chair of the medicine department at the University of California, San Francisco. In deciding whether to prescribe Paxlovid, he said, the benefits significantly outweigh the risks. Some of doctors' doubts will sound familiar to regular readers of this newsletter. The medication is relatively new (in a field that typically takes years to adopt new treatments). They worry about side effects, including diarrhea, muscle pain and an altered sense of taste. They also point to "rebound" Covid cases, which can cause symptoms to come back after subsiding, as happened to Dr. Anthony Fauci and President Biden after they took Paxlovid. (Although Covid symptoms can rebound without Paxlovid.) Doctors also sometimes believe that a patient is not sick enough to prescribe Paxlovid. But the point of Paxlovid is to prevent Covid from getting severe. The medication works best when prescribed in the first few days after a patient shows symptoms, so a doctor does not have time to wait to see how bad an infection gets. Another concern topped a recent survey of medical professionals by the health care website Medscape: potential interactions between Paxlovid and a long list of other drugs. Doctors might see that their patients are on one of those medications and choose not to prescribe Paxlovid. That justification is especially concerning to experts because it is more likely to be used to deny Paxlovid to older patients and those with other health conditions, since they are more likely to be on multiple medications. But these two groups are also among the most vulnerable to Covid hospitalization and death. To avoid harmful drug interactions, experts said, doctors can temporarily get a patient off a medication or provide an alternative during a course of Paxlovid — something they already often do with other treatments. "This is not some extraordinary thing that physicians don't know how to do," said Dr. Ashish Jha, the White House Covid response coordinator. Only two of the 100 most prescribed medications, rivaroxaban (typically prescribed for blood clots) and salmeterol (for lung disease), produce interactions so severe that Paxlovid should be avoided altogether, according to the Infectious Diseases Society of America. Some doctors would also like to see more evidence for Paxlovid. The arc of Covid has changed since Paxlovid started rolling out by early 2022, with more widespread vaccinations and the emergence of new variants. Some physicians want data demonstrating which patients still benefit from the drug, said Dr. Lindsay Petty, an infectious disease doctor at the University of Michigan. Wachter agreed that more data would be good, but argued that the existing studies show convincing evidence of Paxlovid's benefit. "If you're an impartial reader and sit down to look at the research and compare it to other research we used to decide people should take statins or have their blood pressure treated, Paxlovid feels like it's in the same category," he said. Breaking through The White House and health organizations are working to get more physicians to prescribe Paxlovid. They have made some progress in increasing use and closing gaps based on race and class, Jha said. But with Covid still tied to hundreds of deaths and thousands of hospitalizations a day, those advances are slower than anyone would like. As with vaccines and boosters, it's hard to see what will get more Americans to embrace one of the most effective treatments we have for Covid. More Covid news The Biden administration plans to end the coronavirus public health emergency in May, which could limit access to free tests and treatments. Learning loss for children during the pandemic amounted to about one-third of a school year, a study found. Continue reading the main story ADVERTISEMENT THE LATEST NEWS The Death of Tyre Nichols The Memphis Police Department suspended two more officers in connection with Nichols's death. A police report said one officer used a stun gun. The initial police report described Nichols as irate and violent. Video evidence offered a starkly different account. Nichols's parents will attend Biden's State of the Union address next week. Economy A clothing factory in China.Gilles Sabrié for The New York Times The global economy is poised for a rebound as inflation eases and will probably avoid a recession, the International Monetary Fund projected. Europe's economy performed better than expected last year, helped by lower natural gas prices and government financial support. Russia's neighbors and allies have increased trading with the country, aiding its economy despite Western sanctions. If the U.S. fails to raise its debt limit, Wall Street is betting that the Treasury will use an untested trick to try to limit the economic damage. International Secretary of State Antony Blinken is visiting Israel and the occupied West Bank after violence surged in the region. Russia's invasion has put people who sell sex in Ukraine in greater danger of coercion. A suicide bombing at a mosque in Pakistan killed at least 87 people. Politics Manhattan prosecutors presented evidence to a grand jury about Donald Trump's role in paying hush money to a porn star in 2016. The Saudi-backed LIV Golf tour will play three events at Trump's golf courses this year. The White House protects sensitive documents with tracking numbers and burn bags. "Inch by inch": Gabrielle Giffords, the former representative, likens the country's slow progress on gun safety to her long recovery from a mass shooting. Other Big Stories Two monkeys were apparently taken from the Dallas Zoo, the latest among bizarre episodes there including the escape and death of other animals. An interview on Joe Rogan's podcast inspired people to search for mammoth tusks in New York's East River. Bobby Hull, the N.H.L. Hall of Famer who had a fearsome slap shot, died at 84. Opinions Florida banning an A.P. African American Studies course isn't just performative white supremacy; it indoctrinates students with ignorance, Janai Nelson argues. The gulf between the true state of the economy and the public's perception of it is growing, Paul Krugman writes. Expand upon The Morning experience with New York Times All Access. Readers of The Morning now can access everything The Times has to offer, including breaking news and analysis, Games, Cooking, Wirecutter and The Athletic, with the New York Times All Access subscription. Subscribe now at this special rate. MORNING READS Floating saunas in Oslo.David B. Torch for The New York Times 36 Hours: Oslo has reinvented itself. Detox: A juice cleanse might make you feel better, but there's not much science behind it. Well: How long does it take to get fit again? Advice from Wirecutter: It's probably time to replace these household essentials. Lives Lived: Cindy Williams was an actress best known for her role on the 1970s slapstick sitcom "Laverne & Shirley." She died at 75. SPORTS NEWS FROM THE ATHLETIC San Francisco's quarterback: Brock Purdy completely tore his U.C.L. in the 49ers' loss Sunday, setting up a tense off-season for the team. Luka Dončić scores 53: The Mavericks superstar logged his fourth 50-point game of the season last night in Dallas' win over the Pistons. Doctor accused of misconduct: Multiple hockey players in the Detroit suburbs have accused Dr. Zvi Levran of sexual abuse, and prosecutors have charged him with 27 counts of criminal sexual misconduct. Continue reading the main story ADVERTISEMENT ARTS AND IDEAS Amar Kaur, the Punjabi grandmother behind the popular YouTube account Veg Village Food.Veg Village Food In the kitchen with Granny On a recent episode of "Grandmas Project," a web series in which film directors document their grandmothers as they cook at home, a star of the show, Munise Bostanci, wonders who would watch her go about her day. "How typical of a grandma to underestimate her popularity and her reach!" The Times's Tejal Rao writes. It turns out that the internet has a boundless appetite for watching wholesome grandmothers live their lives. Grandfluencers, as they are known, command large audiences on TikTok, Instagram and YouTube. Watching a grandmother cook can be educational and entertaining. It can be deeply nostalgic, too — it's not a coincidence, Tejal notes, that grandfluencer traffic tends to spike around the holidays. PLAY, WATCH, EAT What to Cook David Malosh for The New York Times Eat this quinoa and broccoli salad with a spoon. What to Watch For funny former spies or upbeat flights of anarchy, stream these action movies. What to Read In "Maame," by Jessica George, a young woman strives for independence while carrying the weight of her family's world. Late Night Jimmy Kimmel made fun of Trump's return to the campaign trail. Now Time to Play The pangram from yesterday's Spelling Bee was hyphenate. Here is today's puzzle. Here's today's Mini Crossword, and a clue: Like the sky on a rainy day (four letters). And here's today's Wordle. Thanks for spending part of your morning with The Times. See you tomorrow. P.S. The word "candygate," about M&M's spokescandies rebrand, appeared for the first time in The Times recently. Here's today's front page. "The Daily" is about the Colorado River. Matthew Cullen, Lauren Hard, Lauren Jackson, Claire Moses, Ian Prasad Philbrick, Tom Wright-Piersanti and Ashley Wu contributed to The Morning. You can reach the team at themorning@nytimes.com. Sign up here to get this newsletter in your inbox. Continue reading the main story Need help? Review our newsletter help page or contact us for assistance. You received this email because you signed up for the Morning newsletter from The New York Times, or as part of your New York Times account. To stop receiving The Morning, unsubscribe. To opt out of other promotional emails from The Times, manage your email preferences. Subscribe to The TimesGet The New York Times app Connect with us on: Change Your EmailPrivacy PolicyContact UsCalifornia Notices The New York Times Company. 620 Eighth Avenue New York, NY 10018